4D Molecular Therapeutics, Inc.
General ticker "FDMT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $408.1M (TTM average)
4D Molecular Therapeutics, Inc. follows the US Stock Market performance with the rate: 54.5%.
Estimated limits based on current volatility of 3.0%: low 8.73$, high 9.27$
Factors to consider:
- Earnings expected soon, date: 2026-05-14 amc
- Total employees count: 227 (+54.4%) as of 2024
- US accounted for 100.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Limited operating history and no commercial products, High R&D costs, Regulatory and compliance, Need for additional capital, Rapid industry changes
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.00$, 13.84$]
- 2026-12-31 to 2027-12-31 estimated range: [3.72$, 10.65$]
Financial Metrics affecting the FDMT estimates:
- Positive: with PPE of -3.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -22.96 <= 0.07
- Positive: Shareholder equity ratio, % of 89.23 > 64.25
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term FDMT quotes
Long-term FDMT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $20.72MM | $0.04MM | $85.21MM |
| Operating Expenses | $133.59MM | $187.88MM | $244.76MM |
| Operating Income | $-112.87MM | $-187.84MM | $-159.55MM |
| Non-Operating Income | $12.03MM | $26.97MM | $19.44MM |
| R&D Expense | $97.10MM | $141.30MM | $195.70MM |
| Income(Loss) | $-100.84MM | $-160.87MM | $-140.11MM |
| Profit(Loss)* | $-100.84MM | $-160.87MM | $-140.11MM |
| Stockholders Equity | $307.83MM | $510.61MM | $505.66MM |
| Assets | $339.89MM | $560.38MM | $566.71MM |
| Operating Cash Flow | $-75.79MM | $-134.59MM | $-109.08MM |
| Capital expenditure | $2.77MM | $3.79MM | $0.54MM |
| Investing Cash Flow | $115.72MM | $-302.44MM | $-92.97MM |
| Financing Cash Flow | $156.83MM | $337.25MM | $112.96MM |
| Earnings Per Share** | $-2.58 | $-2.98 | $-2.42 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.